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Abstract
The feasibility of employing nonintegrating lentiviral vectors has been demonstrated by recent
studies showing the ability of nonintegrating lentiviral vectors to maintain transgene expression in
vitro and in vivo. Furthermore, HIV-1 vectors packaged with a mutated integrase were able to correct
retinal disease in a mouse model. Interestingly, these results differ from earlier studies in which first-
generation nonintegrating lentiviral vectors yielded insignificant levels of transduction. However, to
date a rigorous characterization of transgene expression from the currently used self-inactivating
(SIN) nonintegrating lentiviral vectors has not been published. Here we characterize transgene
expression from SIN nonintegrating lentiviral vectors. Overall, we found that nonintegrating vectors
express transgenes at a significantly lower level than their integrating counterparts. Expression from
nonintegrating vectors was improved upon introducing a longer deletion in the vector’s U3 region.
A unique shuttle-vector assay indicated that the relative abundance of the different episomal forms
was not altered by the longer U3 deletion. Interestingly, the longer U3 deletion did not enhance
expression in the corpus callosum of the rat brain, suggesting that the extent of silencing of episomal
transcription is influenced by tissue-specific factors. Finally, and for the first time, episomal
expression in the mouse liver was potent and sustained.
INTRODUCTION
A number of recent clinical trials have demonstrated the efficacy of retroviral vectors as a
means of delivering therapeutic transgenes to patients [1–3]. However, retroviral vectors carry
an inherent risk of insertional mutagenesis, leading to oncogenic transformation of target cells.
This risk has been documented in animal models [4] and has been borne out in a recent clinical
trial, in which four out of ten patients receiving retrovirally corrected cells as treatment for X-
linked severe combined immunodeficiency (X-SCID) developed leukemia [5,6].
Employing nonintegrating, HIV-1-based vectors provides a logical strategy to alleviate the risk
of insertional mutagenesis associated with traditional retroviral vectors. This approach is
premised on the fact that retroviral episomal forms were observed to constitute the vast majority
of viral DNA following transduction, and were found stable in nondividing cells [7–12]. The
episomal viral genomes appear in four forms: linear episomes, which may also serve as
precursors to integration, and 2-LTR, 1-LTR, and aberrant circular episomes, which have been
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suggested to form through host-mediated DNA repair, incomplete reverse transcription, and
autointegration, respectively [13–16]. Current findings in the field of retroviral vectors
demonstrate that nonintegrating lentiviral vectors are capable of mediating significant gene
expression and imparting clinically relevant correction of genetic disease models in vivo [17,
18]. These results are seemingly not in line with previous findings in retrovirus biology, which
indicated that integration is essential for HIV replication [19,20] and that integrase-deficient
HIV is capable of relatively low levels of viral gene expression [21–23]. Furthermore,
nonintegrating first-generation lentiviral vectors also displayed low to negligible transgene
expression [24–27], Importantly, subsequently developed SIN vectors demonstrated
measurable episomal transgene expression in vitro and in vivo [18,28–30]. The improved
efficiency of episomal expression exhibited by U3-truncated SIN vectors suggests that cis-
acting sequences in the U3 may negatively regulate expression. Indeed, a sequence element in
the 5’ U3 region has been shown to reduce both LTR-driven and internally promoted expression
[31–33]. However, the level and efficiency of episomal lentiviral expression has not been
rigorously characterized.
Here, we present an analysis of episomal expression from nonintegrating vectors. We report
that, while the expression levels of episomal lentiviral genomes remained well below that of
integrated lentiviral provirus, a long U3 deletion significantly improved expression from
nonintegrating lentiviral vectors, both in vitro and in vivo. The deletion, however, did not
change the relative abundances of the four episomal forms in transduced cells, suggesting that
the increase in expression cannot be attributed to a distinct episomal vector form. Furthermore,
the expression-enhancing effect of the U3 deletion showed tissue specificity in the rat brain,
which is in line with earlier studies demonstrating cell type-dependent gene expression levels
from nonintegrating HIV-1 [22]. Finally, we report for the first time that episomal HIV-1
vectors achieved strong and sustained transgene expression in the mouse liver. These findings
demonstrate that nonintegrating lentiviral vectors may provide an effective means of delivery
of therapeutic transgenes to nondividing and slowly dividing cells in vitro and in vivo.
RESULTS
Increased in vitro episomal expression from a vector with a large U3 deletion
Several groups recently demonstrated notable in vitro and in vivo expression from
nonintegrating, self-inactivating (SIN) lentiviral vectors [17,18,28,30,34]. These results are
not in line with previous studies on integrase-deficient lentiviral vectors, which exhibited low
to negligible viral gene expression from genomes with full-length U3 regions [24,26,27].
Furthermore, as shown below, an HIV vector containing a short SIN deletion produced
comparatively low episomal expression. To investigate the possibility that a larger U3 deletion
on a SIN vector could enhance its expression, two SIN vectors were made, one bearing a short
U3 deletion (vTK113, deleted from –7 to –141, as in the vector described by Miyoshi et al.
[35]), and one containing a larger U3 deletion (vTK945, deleted from –48 to –396, thus
retaining the TATA box)(Fig. 1a)(deletions outlined in Fig. S1, see Fig. S2 for a full list of
vectors used for this study); both vectors were packaged with functional or deficient integrase
and used to transduce 293T cells (Fig. 1b). To minimize the risk of expressing saturating
quantities of GFP, thereby confounding subsequent GFP expression analysis, cells were
transduced with decreasing amounts of vector, and target-cell populations exhibiting <60%
transduction were analyzed by FACS analysis at five days posttransduction for GFP
expression. As shown in Fig. 1b, a larger U3 deletion increased episomal expression of GFP
nearly threefold, from an MFI of 28.34 for the nonintegrating short-deletion vector vTK113/
IN- to an MFI of 82.10 for the nonintegrating long-deletion vector vTK945/IN-. However,
regardless of the length of the U3 deletion, integrating vectors expressed more GFP than either
nonintegrating vector, and the difference between the levels of transgene expression exhibited
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by vTK113/IN+ and vTK945/IN+ was not significant. Not surprisingly, after four passages
GFP was not detected by FACS analysis in cells transduced with nonintegrating vectors (Fig.
1b), and less than 0.1% of cells displayed GFP measurable by fluorescence microscopy (data
not shown).
To support further the notion that U3 sequences inhibit transcription, a Northern-blot assay
was employed to measure the effect of U3 deletion length on transcription in 293T cells. Cells
were transduced as for FACS and RNA was harvested, hybridized to a radiolabeled,
woodchuck hepatitis virus posttranscriptional regulatory element (WPRE)-specific probe,
which recognizes transcripts both originating from the internal CMV promoter and LTR-
derived transcripts, and quantified via phosphorimager. In keeping with FACS analysis, the
Northern assay indicated that the larger U3 deletion enhanced episomal transcription nearly
fourfold, that both integrating vectors produced significantly more RNA than either
nonintegrating vector, and that short-deletion and long deletion integrating vectors generated
comparable levels of RNA (Fig. 1c, Table S1). Also of note are the two transcripts produced
by nonintegrating vTK113 and vTK945, in which the lower, stronger band corresponds to a
normal, CMV-derived transcript, while the higher, weaker band, significantly higher for
vTK113 than vTK945, is suggestive of transcriptional readthrough on 2-LTR circular
episomes, such that termination occurs at the distant LTR’s polyA site; in such a case,
vTK945’s larger U3 deletion would produce a smaller readthrough product than vTK113’s
(Fig. 1c). Furthermore, full-length transcripts were not detected, indicating that vTK113 and
vTK945 are SIN vectors, despite the presence of a TATA box in vTK945’s U3. These findings
are in line with a prior study by Zufferey et al. that also failed to detect full-length transcription
from SIN vectors with TATA-containing U3 sequences [36]. However, mindful of the
possibility that the TATA box in vTK945 may contribute to its increased episomal expression,
we constructed a new vector (vTK1125, Figs. S1 and S2) containing a state-of-the-art U3
deletion from (–18 to –418, as described in Zufferey et al.) that eliminates the TATA box and
5’ U3 sequences. Interestingly, extending the deletion in the U3 to include the TATA box did
not improve episomal transgene expression beyond the levels obtained by vTK945 (Fig. S3).
Finally, the notion that the larger U3 deletion mediates increased episomal expression was
further confirmed by a qPCR-normalized luciferase assay comparing short-deletion (vTK464)
and long-deletion (vTK993) vectors (Fig. S4).
Relative abundances of episomal forms are unaffected by U3 deletion length
These results were in line with earlier studies suggesting that the U3 sequence contains an
expression-repressing element in its 5’ region [31–33,37]. However, we could not rule out the
possibility that other factors account for the increase in expression associated with the long U3
deletion in vTK945. To date, there is no indication that the various episomal forms (2-LTR
circular, 1-LTR circular, mutant, and linear) express transgenes with differing efficiencies.
Thus, the question remains of whether the increased episomal expression generated by
nonintegrating long U3-deletion vectors is associated with a concomitant change in the relative
abundance of episomal forms. Similar to earlier studies characterizing the relative abundance
of vector episomes and integrated provirus [15,29,38], Southern analysis was employed on
DNA extracted from transduced Jurkat and 293T cells at three days posttransduction and
following three passages (Fig. 2a). As shown in Fig. 2b and quantified in Table 1, the relative
abundance of episomal forms in integrating and nonintegrating vectors was not changed
significantly by the longer U3 deletion. However, and in keeping with a prior study [39],
differences in relative episomal abundance were caused by integrase status, with nonintegrating
vectors producing significantly more 2-LTR circles than integrating vectors, and by cell type,
with 293T cells exhibiting a notably greater proportion of linear episomes than Jurkat cells.
Interestingly, and differing from a recent report [29], the relative abundance of linear episomes
was not dramatically upregulated by integrase deficiency (Fig. 2b). Under the condition of
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harvesting DNA three days posttransduction, linear episomes were comparable to, and in some
cases exceeded by, 1-LTR circles in terms of relative abundance (Table 1). Furthermore,
integrated provirus accounted for between 21 and 33% of all vector genomes, regardless of U3
deletion size (Fig. 2b). While Southern-blot analysis did not show significant changes in
episome formation mediated by U3 length, cell line-specific changes were noted, with all
vectors producing a greater share of linear episomes and a smaller proportion of 1-LTR circles
in 293T cells than in Jurkat cells (Fig. 2b). Prior studies on simple retroviruses demonstrated
the existence of autointegrated lentiviral episomes [16]; however, the relative contribution of
this unique episomal form to the total population of episomes in the context of lentiviral/
retroviral vectors has not been elucidated, largely because autointegrated episomes, being
variably sized, cannot be adequately detected by Southern blot. To overcome this technical
difficulty, we developed an HIV-1-derived shuttle vector containing a bacterial origin of
replication and a drug-resistance gene within the vector’s transcribed region. This vector
configuration enables circular episomes produced in vector-transduced cells to be extracted by
the Hirt protocol [40], and monoclonally isolated from bacteria (Fig. 2c). Simple restriction
analysis allows individual episomal clones to be characterized either as 1-LTR, 2-LTR, or
autointegrated circles. As shown in Fig. 2d (and in keeping with previous results [7,39]), results
of the shuttle-vector assay indicate that, in integrating-vector-transduced cells, 1-LTR circular
episomes, 2-LTR circular episomes, and autointegrated circular episomes account for roughly
75%, 15%, and 10% of circular episomes, respectively, while in nonintegrating vector-
transduced-cells, their relative amounts were 60%, 35%, and 5%, respectively. Shuttle vectors
bearing a full-length LTR (vTK459, described in detail in Ma et al., [41]), a short U3 deletion
(vTK1055), or a long U3 deletion (vTK1054)(Fig. S2) were assayed, leading to the finding
that U3 length did not affect the relative abundances of circular episomes, with the notable
exception that vTK1054 demonstrated significantly more autointegrated episomes than
vTK459 (p-value of 0.0005 by chi2 test)(Fig. 2d, Table S2).
Increased episomal expression in the brain and liver from a vector with a large U3 deletion
In accordance with the notion that lentiviral episome formation may vary across cell types,
previous findings indicate that the level of episomal lentiviral gene expression may be cell
type-specific [22]. These findings spurred an investigation into the ability of nonintegrating
lentiviral vectors to transduce effectively a variety of cell types in vivo. Accordingly, rats were
injected intracranially with equal transducing units of integrating and nonintegrating small-
deletion (vTK113) and long-deletion (vTK945) vectors. Two weeks and three months after
striatal infusion, brain tissues were harvested and imaged for GFP, as well as the neuron-
specific marker NeuN and the astrocyte-specific marker GFAP. As shown in Fig. 3a, the U3
deletion notably increased episomal GFP expression in striatal tissue three months postinfusion
(Fig. S5 shows similar results two weeks postinfusion). However, while nonintegrating
vTK113 expressed GFP in both neurons and astrocytes, nonintegrating vTK945 appeared to
transduce astrocytes to a significantly lesser degree (Fig. 3b). Furthermore, while vTK945
expressed GFP strongly in the striatum, episomal expression of vTK945 in the corpus callosum
was relatively weak (Fig. 3a). Intrigued by the long U3 deletion’s effect on episomal expression
in the rat brain, we sought to replicate the vector’s efficacy in the slowly dividing tissue of the
liver, which prior findings had found resistant to sustained episomal lentiviral transduction
[27]. To that end, mice were injected intraperitoneally with 100 μg p24 of small-deletion
(vTK647) or large-deletion (vTK979) vector expressing luciferase from the liver-specific
promoter hAAT. After imaging for luciferase activity at 10 days, 45 days, and 6 months
postinjection, nonintegrating vTK979 was found to generate roughly fourfold more luciferase
activity than nonintegrating vTK647, but still yielded approximately 40-fold less luciferase
activity than integrating vTK647 (Fig. 3c and d). Furthermore, in disagreement with a previous
report, we found that transgene expression in the liver was largely stable over a six-month time
course [42](Fig. 3c and d). Taken together, the results in Fig. 3 indicate that the U3 deletion
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improves episomal expression in several tissues in vivo, and that the effect is sustained over
time.
DISCUSSION
The overall goal of this study was to characterize episomally derived transgene expression
from SIN lentiviral vectors, in vitro and in vivo. In general, while all vectors demonstrated
measurable levels of transgene expression regardless of the SIN vector used, nonintegrating
vectors exhibited significantly less transgene expression than their integrating counterparts.
This finding represents a notable discrepancy with recent reports concerning nonintegrating
vectors, which do not indicate any major difficulty in obtaining robust expression from
nonintegrating vectors [17,30]. Differences of methodology in quantifying expression may
explain the discrepancy. Specifically, in the present study efforts were made to evaluate the
efficiency of expression by Northern analysis and direct measurement of transgene abundance,
either by mean fluorescence index (MFI) or by relative light units (RLU); furthermore, to avoid
saturation, transduction was carried out at low m.o.i. and expression was normalized to vector
copy number. Conversely, previous reports measured the percentage of cells expressing a given
transgene; this method does not measure the degree of expression in a transgene-positive cell.
Another methodological concern is that expression from integrating vectors, if measured
shortly after transduction or from nondividing cells, is generated primarily from episomes,
which account for 70–95% of vector genomes [7,9,12]. Therefore, early expression seen from
cells transduced with integrating vectors may still be largely episome-derived and not as
efficient, on average, as expression from exclusively integrated genomes, possibly leading to
the undervaluation of expression generated from integrated provirus. However, the mechanism
by which expression from unintegrated lentiviral genomes is repressed is not clear. The fact
that the earliest lentiviral vectors exhibited the lowest level of episomal expression raised the
possibility that a cis element in the U3 region may inhibit transcription from lentiviral vectors,
and, in fact, early studies on HIV-1 suggest the existence of such an element [32,33,37]. While
the effect of the long U3 deletion on episomal expression implies that cis–acting elements in
the lentiviral vector genome influence extrachromosomal transcriptional activity, the
possibility exists that cell-specific trans-acting factors are also involved in the mechanism of
downregulated transgene expression from lentiviral episomes. In keeping with the concept of
cell-specific factors influencing episomal expression, previous findings indicate varying levels
of gene expression across a number of cell lines infected with nonintegrating lentivirus [22].
Interestingly, transduction of murine dorsal root ganglia in culture by wild-type U3 or long
U3-deletion lentiviral vectors resulted in strong expression exclusively in neurons, or both
neurons and stromal cells, respectively, further suggesting that the silencing mechanism of
retroviral vector expression bears cell-specific characteristics [31].
The potentially variable nature of episomal expression and U3-mediated transcriptional
repression across cell types, coupled with the clinical relevance of in vivo transduction,
underscored the importance of measuring gene expression in a variety of cell types in vivo.
Here we show that the large U3 deletion had a pronounced effect on episomal expression in
rat-brain striatal cells; however, this improvement in SIN vector design did not confer robust
episomal expression in corpus callosum cells, suggesting that additional mechanistic elements
contribute to the silencing of episomal expression. The possibility that increased efficiency of
expression from long U3-deletion vectors is due to differences in episome formation is ruled
out by the present study, which indicates that no significant change in the relative abundances
of episomal forms is associated with the large U3 deletion. However, analysis of episome
formation revealed discrepancies with published results. In contrast to a prior report, the
relative abundance of linear episomes did not increase in the absence of functional integrase
[29]. In keeping with the findings of Svarovskaia et al. [39], the relative abundance of 2-LTR
circular episomes increased in the absence of integrase activity. Two putative mechanisms
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proposed earlier by Engelman et al. [43] to explain this phenomenon suggest either that blunt-
ended, linear DNA, unprocessed by mutant integrase, is more amenable to circularization by
end-joining, or that more linear DNA is available for circularization in the absence of integrase
activity. Interestingly, the efficiency of integration in the present study, as measured by
Southern blot, ranged from 23% to 35% of all integrase-functional vector genomes, which is
higher than the 5–16% measured previously by PCR [7]. The present study employed a novel
shuttle-vector assay to quantify the autointegrated circular episomal form produced by
lentivectors, and observed that integrase-deficient vectors produced a measurable number of
autointegrated circles, suggesting that the mechanism of their formation may be partly
integrase-independent. Furthermore, integrating long U3-deletion vectors were found to
produce notably more autointegrated circular episomes than did other vectors, implying that
U3 sequences help prevent the formation of autointegrated circles.
Prior studies administered nonintegrating vectors in vivo by direct injection into nondividing
target organs, including eye, brain or muscle [17,18,34], thereby delivering potentially
saturating quantities of vector particles; however, the present study, for the first time,
administered nonintegrating lentiviral vectors systemically to slowly dividing liver cells, which
allowed testing of the vector’s efficacy in a condition of low concentration and, by extension,
relatively low multiplicity of infection in the target organ. Intriguingly, a long U3-deletion
vector expressed four times more liver-specific luciferase than a short U3-deletion vector, in
keeping with in vitro results and indicating that cells in the liver may express transcriptionally
repressive factors binding to the 5’ U3 region eliminated from the large U3-deletion vector.
The significant, hepatocyte-specific luciferase expression noted by the present study contrasts
with previous reports characterizing episomal lentiviral expression in the liver as insignificant
[27]; discrepancies with the prior study may be due to differences in transgene employed and
LTR length. Furthermore, in divergence from prior findings suggesting that liver-specific
lentiviral vector transgene expression induces an effective immune response [42], the present
study found no significant loss of expression in immunocompetent mice. In fact, transgene
expression from every vector assayed was sustained for at least six months after administration,
in agreement with prior studies stably expressing transgenes episomally in the liver from adeno-
associated viral vectors and plasmid DNA [44,45]. A slight reduction over time of episomal
expression in mouse livers observed in this study may be due to the slow division of liver cells,
and could eventually necessitate readministration of alternately pseudotyped vector.
In summary, the present study showed that a nonintegrating lentiviral vector with an
extensively truncated U3 region can be an efficacious means of delivering transgenes to target
cells in vivo. However, the fact that nonintegrating long-deletion lentiviral vectors still do not
express transgenes as efficiently as their integrating counterparts indicates that an additional
mechanism of episomal silencing may be involved, possibly one that is inherent to unintegrated
retroviral genomes. The transcriptional downregulation of lentiviral episomes, combined with
the fact that they are not influenced by the chromosomal transcriptional regulatory
environment, indicate that the characteristics of integrated lentiviral genomes cannot be
extrapolated to lentiviral episomes, and that further characterization of nonintegrating lentiviral
vectors is required to optimize their use in basic research and gene therapy applications.
MATERIALS AND METHODS
Lentiviral vector constructs
The vector cassette pTK113 has been described previously [46] and contains a U3 deletion
extending from –7 to –141. The vector cassette pTK945 bears a U3 deletion spanning –48 to
–396, and is otherwise identical to pTK113. The vector cassette pTK1125 bears a U3 deletion
extending from –18 to –418, and is otherwise identical to pTK113. Shuttle vectors were derived
from the vector plasmid pTK459 [41], which includes a bacterial origin of replication and
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ampicillin-resistance gene in the transcribed region of the plasmid, as well as a full-length U3
(in pTK459), short-deletion U3 (pTK1055), or long-deletion U3 (pTK1054). The vector
cassettes pTK647 and pTK979 were constructed by inserting the U3 sequence from pTK113
and pTK945, respectively, into pTK646, which bears the liver-specific promoter hAAT and
the firefly luciferase gene, by standard cloning procedures. The Flp9 cell line was prepared as
follows: pTK113 was cloned into Flp-In expression vector (Invitrogen, Carlsbad, CA) and the
resulting plasmid was cotransfected with pOG44 (Flp recombinase) into the Flp-InTM host cell
line, such that pTK113 integrated into the genomic FRT site (Invitrogen). The single-copy
incorporation of the expression cassette per diploid genome was verified by Southern blot,
following digestion of DNA isolated from Flp9 cells with AflII (New England Biolabs,
Ipswich, MA, and all restriction enzymes to follow), which recognizes 2 sites in the LTR of
the expression vector, or XbaI, which recognizes a single site in each FRT sequence.
Viral vector production
All lentiviral vectors were prepared as previously described [46], transiently transfecting 107
293T cells with 15μg vector cassette, 10μg packaging cassette, and 5μg envelope cassette.
Integrating vectors were made using the packaging cassette ΔNRF [46], which expresses
functional integrase, while nonintegrating vectors were made using the packaging cassette
pTK939, which was made by inserting the D64E-mutant integrase from pD64E into ΔNRF by
standard cloning procedures. All vectors were pseudotyped with the VSV-G envelope cassette.
For vectors constitutively expressing GFP, titers were assessed by serial dilution in 293T cells
followed by visual analysis of GFP expression by fluorescence microscope. For other vectors,
concentrations were determined by p24gag ELISA. The absence of replication-competent
retroviruses was determined by three independent methods: tat transfer assay, vector rescue
assay, and p24gag ELISA, as described previously [47].
Cell culture
293T cells were grown in Dulbecco's modified Eagle medium (Mediatech, Herndon, VA)
supplemented with 9% fetal bovine serum and 1% penicillin/streptomycin solution. Jurkat cells
were cultured in Roswell Park Memorial Institute medium (Mediatech) supplemented with 9%
fetal bovine serum and 1% penicillin/streptomycin solution.
FACScan analysis
293T cells were transduced at an m.o.i. of 1. At 3–5 days (p0) and four passages (p4)
posttransduction, cells were harvested, fixed in 1X PBS containing 2% formaldehyde/0.2%
glutaraldehyde, and analyzed by FACscan as peviously described [48].
Northern blot analysis
293T cells were transduced with the indicated vectors at an m.o.i. of 1. Total cell lysates were
prepared 3–5 days posttransduction for RNA isolation using the PARISTM kit (Ambion,
Austin, TX) or Rneasy® Plus Mini kit (Qiagen, Hilden, Germany). 3mg of total RNA was
denatured at 70°C and resolved on a 1.2% denaturing formaldehyde/agarose gel. RNA was
transferred to a Zeta-Probe GT® membrane (BioRad, Hercules, CA). Hybridization was
executed at 68°C for ~18 hours with a 32P-labeled probe comprising a 595-base region spanning
the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) that was cut
from pTK113 with ClaI. The Northern blot image was imaged with BioMax MR film (Kodak,
Rochester, NY). Relative quantification of RNA species was obtained via Storm
phosphorimager (GE Healthcare, Chalfont St. Giles, UK) using ImageQuant 5.2 software (GE
Healthcare).
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Cells were harvested three days and three passages after transduction with vTK113 and
vTK945 and their total DNA was extracted using the Qiagen Blood and Cell Culture DNA
Midi Kit (Qiagen). 10μg total DNA was digested with DpnI and either EcoNI and PflMI (for
293T cells) or NotI and PflMI (Jurkat cells), electrophoresed in a 1% gel, transferred to a nylon
membrane (GE Healthcare), UV-crosslinked, and probed with the 1.4kb KasI/BamHI fragment
of vTK945. To control for loading, membranes were also probed with a 731bp region of the
endogenous gene BDNF, produced with the PCR primers
5'CGTTTGACCAATCGAAGC3' (forward) and
5'TCCCCTCAGTCAGGACCCTCG3' (reverse). Quantification of DNA density was achieved
on a Storm phosphorimager using ImageQuant 5.2 software.
Shuttle vector assay
293T cells were transduced with integrating or nonintegrating vTK459, vTK1055, and
vTK1054 (Fig. S2). Transduced cells were harvested 16 hours posttransduction using 0.85mL
Hirt lysis buffer and 0.25mL 5M NaCl per 10cm plate of transduced cells. Episomal DNA was
subsequently subjected to phenol/chloroform extraction and DpnI digestion and electroporated
into bacteria. Bacterial colonies were cultured monoclonally, pelleted, and their episomes
extracted by boiling in a hotprep buffer made with 2g sucrose, 0.4mL 0.5M Tris/EDTA
solution, 40mL 10% Triton X-100 (Sigma, St. Louis, MO), 5mL 1M Tris/HCl pH 8.0 and water
to 100mL. 125μL hotprep buffer and 2.5μg RNase A (Sigma) were added to each bacterial
pellet before boiling. After boiling, samples were centrifuged at 14K for 10 minutes to dispose
of cell debris. Episomes were digested with NotI and SacII and electrophoresed in a 1% agarose
gel to be characterized as 1-LTR, 2-LTR, or mutant circular episomes. For every transduction,
between 73 and 112 episome-bearing bacterial colonies were characterized.
In vivo experiments in rat brain
All of the animals were pathogen-free male Sprague-Dawley rats obtained from Charles Rivers.
All care and procedures were in accordance with the Guide for the Care and Use of Laboratory
Animals (DHHS Publication No. [NIH]85-23), and all procedures received prior approval by
the University of North Carolina Institutional Animal Care and Usage Committee. Virus vector
infusions were performed as previously described [49]. Briefly, rats first were anesthetized
with 50 mg/kg pentobarbital and then placed into a stereotaxic frame. Using a 32 gauge stainless
steel injector and a Sage infusion pump, the rats received 1 ml (at 6 x 109 GFP transducing
units/mL) of the integrating and nonintegrating vTK113 and vTK945 vectors over a 10 minute
period into the striatum (1.0mm anterior to bregma, 3.0mm lateral, 5.5mm vertical) according
to the atlas of Paxinos and Watson [50]. In all cases, the injector was left in place 3 minutes
postinfusion to allow diffusion from the injector.
Immunohistochemistry
Two weeks or 3 months after the vector infusion, rats received an overdose of pentobarbital
(100 mg/kg pentobarbital, i.p.) and subsequently were perfused transcardially with ice-cold
100 mM sodium phosphate buffered saline (PBS) (pH=7.4), followed by 4% paraformaldehyde
in 100 mM phosphate buffer (pH=7.4). After overnight fixation in paraformaldehyde-
phosphate buffer, vibratome sections (40 mm thick) were taken through the striatum and rinsed
in PBS. For immunohistochemistry, tissue sections were incubated in 10% normal goat serum
and 0.1% Triton X-100 in PBS for 45 minutes. Next, sections were incubated with a primary
antibody to NeuN (1:500, Chemicon, Temecula, CA) or glial fibrillary acidic protein (GFAP)
(1:4,000, DAKO A/S, Denmark) overnight in 3% normal goat serum, 0.2 % Triton X-100 and
PBS. Tissue sections were then rinsed in PBS, incubated in blocking serum (10% normal goat
serum, 0.1% Triton X-100, PBS) for 1hr. and then incubated with a secondary fluorescent
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antibody (Alexa-fluor 594 goat anti-mouse (NeuN), goat anti-rabbit (GFAP), (Molecular
Probes, Eugene, OR) for 1 hour at 40C. Following 3 rinses in PBS, the sections were mounted
on slides and coverslipped with fluorescent mounting media. eGFP fluorescence initially was
visualized on an Olympus IX 71 fluorescence microscope (Olympus, Center Valley, PA), and
digital pictures were taken. In the cases where co-localization was to be determined, both the
GFP and the Alexa 594 fluorescence was visualized with a Zeiss 510 Meta laser scanning
confocal microscope (Zeiss, Oberkochen, Germany). Co-localization was determined by
multiple scans through the Z axis of the sample.
In vivo experiments in mouse liver
All procedures received prior approval by the University of North Carolina Institutional Animal
Care and Usage Committee. C57BL/6NHsd mice (Harlan Sprague Dawley, Indianapolis, IA)
were injected intraperitoneally at eight weeks of age with 100μg p24 of lentivector. At 10 days,
45 days, and 6 months postinjection mice were assayed for luciferase expression following
luciferin (NanoLight, Pinetop, AZ) injection and using the Xenogen IVIS imaging system
(Xenogen, Hopkinton, MA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Comparative analysis of in vitro expression from lentiviral vectors with short or long deletions
in the U3 sequence. (a) Schematic of vectors with partial (vTK113) or larger (vTK945) U3
deletions; deleted sequences are indicated by crosshatching. (b) FACS analysis of GFP
expression generated by vTK113 (left) or vTK945 (right), with (upper) or without (middle and
lower) functional integrase, in 293T cells. Mean fluorescence intensity (MFI) was measured
5 days posttransduction (p0) and after four passages (p4) (lower). (c) Northern-blot analysis
of transcription mediated by short-deletion (lanes 1 and 3) or long-deletion (lanes 2 and 4)
vectors, with (lanes 1 and 2) or without (lanes 3 and 4) functional integrase, in 293T cells. RNA
was harvested 5 days posttransduction. Equal loading of RNA was verified through ethidium-
bromide staining of ribosomal RNA (lower panel).
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Analysis of episome formation in cells transduced with lentiviral vectors. (a) To
simultaneously analyze integrated and nonintegrated vector genomes, total DNA from
transduced cells was cut at sites (EcoNI and PflMI) flanking the LTR(s), and a radiolabeled
probe complementary to a region spanning the EcoNI site was employed on vTK113 (left) and
vTK945 (right) vector genomes. (b) Episome formation and integration efficiency was
examined by Southern blot in Jurkat (upper) and 293T (lower) cells. Jurkat cells were
transduced with vTK113, integrating (lanes 1 and 3) or nonintegrating (lanes 2 and 4), or with
vTK945, integrating (lanes 5 and 7) or nonintegrating (lanes 6 and 8) and total DNA was
extracted from transduced cells 3 days (no passages)(lanes 1–2 and 5–6) or ~14 days (3
passages)(lanes 3–4 and 7–8) posttransduction, digested as shown in (a), and analyzed by
Southern blot, and the same procedure was followed using 293T cells (lanes 9–16). Size
markers are shown in red. (c) Outline of the shuttle-vector assay for characterizing the relative
abundance of circular episomes. (d) Episomes were harvested from 293T cells 16 hours
posttransduction; each transduction was performed in triplicate.
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Analysis of in vivo episomal expression from lentiviral vectors with short or large deletions in
the U3 sequence. (a) Tissue compartment-specific GFP expression mediated by short-deletion
or long-deletion vectors, with (top) or without (bottom) functional integrase, in the striatum
and corpus callosum of the rat brain, measured three months after vector infusion. (b) Cell
type-specific GFP expression mediated by short-deletion (lower) and long-deletion (upper)
nonintegrating vectors in neural (fluorescing with NeuN, left side) and glial (fluorescing with
GFAP, right side) cells of the rat brain, measured three months after vector infusion. A 20-
micron size bar appears in the 113/IN- GFAP/GFP merge panel. (c) Long-term luciferase
expression produced by short-deletion or long-deletion vectors, with or without functional
integrase, in the mouse liver. Animals were imaged 10 days, 45 days, and 6 months after
intraperitoneal injection of vector. (d) Quantification of luciferase expression described in
(c). Each bar represents the average of luciferase measurements from three mice.
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